What happened with leucovorin for autism claims?
FDA walked back leucovorin’s autism pitch after Trump/RFK Jr. promotion
Leucovorin surfaced as an autism-related treatment after public promotion by Donald Trump and Robert F. Kennedy Jr. In the wake of that attention, outpatient prescriptions for the drug increased sharply, reflecting how quickly demand can follow high-profile claims—especially when families are searching for interventions.
The FDA later clarified limits on its use. Instead of endorsing leucovorin as a general treatment for autism, regulators approved it only for a specific, narrower medical purpose: folate deficiency. That distinction matters because leucovorin is chemically related to folate pathways, and the FDA’s approval tied to folate deficiency signals the regulator’s stance that the drug’s role is condition-specific rather than broadly validated for autism.
Why this matters
This episode highlights a recurring problem in health communication: when influential political figures elevate an off-label or insufficiently proven therapy, demand can surge before the evidence base is fully established. For clinicians and patients, the FDA’s later narrowing of the approved indication can affect prescribing decisions and how quickly resources shift in a market.
Key practical implications include:
- Patients may seek the medication based on non-regulatory endorsements.
- The medication’s medically appropriate use may differ from what headlines imply.
- Regulators may need to act to prevent misunderstanding about approved indications.
What’s still not specified
The stories provide clear information that prescriptions rose after promotion and that FDA approval was limited to folate deficiency. But they do not give details on any autism-specific trial results or whether clinicians broadly changed practice beyond prescribing trends.
Overall, the sequence—promotion, rising prescriptions, then FDA clarification—underscores the gap that can exist between public messaging and formal regulatory approval.